^
Association details:
| Biomarker: | AR F877L + AR T878A |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Excerpt:
Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR.
DOI:
10.1158/1535-7163.MCT-15-0892
